Adderall has been around since 1996 in its current form, but the drug it evolved from dates back to the late 1950s. The amphetamine mixture at its core was first approved by the FDA in 1960 under a different name, making the underlying medication more than six decades old.
From Weight Loss Pill to ADHD Treatment
Adderall’s story starts with a drug called Obetrol, a mix of amphetamine salts originally marketed as a weight loss pill. Obetrol’s FDA application was conditionally approved on July 24, 1958, and made fully effective on February 23, 1960. The original patent holder was Rexar Pharmacal Corp. For decades, Obetrol existed as one of many amphetamine-based diet pills on the market.
In the 1990s, Obetrol was reformulated and rebranded as Adderall, this time targeting ADHD rather than obesity. The new name, reportedly a play on “A.D.D. for All,” reflected a completely different market. It entered a field dominated by Ritalin and quickly became a serious competitor because of its potency and longer-lasting effects.
What’s Actually in It
Adderall contains equal amounts by weight of four amphetamine salts. The specific combination produces a 3.1-to-1 ratio of dextroamphetamine to levoamphetamine. Dextroamphetamine is the more stimulating form, while levoamphetamine acts somewhat differently in the body and contributes to the drug’s longer duration. This four-salt formula has remained essentially unchanged since the 1990s rebranding.
Key Dates in Adderall’s Timeline
The drug hit several milestones over the years. The original amphetamine mixture gained full FDA approval in 1960 as Obetrol. It was reformulated and launched as Adderall for ADHD in 1996. An extended-release version, Adderall XR, received FDA approval in 2001. That formulation uses two types of beads inside each capsule: one set releases immediately and the other releases hours later, stretching the effect across a full day rather than requiring a second dose.
Generic versions of the immediate-release tablet became available in February 2002, when Teva Pharmaceuticals launched multiple dosage strengths. The arrival of generics made the drug significantly more affordable and accessible, which helped fuel its rapid growth in prescriptions over the following two decades.
How Prescriptions Have Grown
Adderall’s rise from a niche ADHD medication to one of the most prescribed drugs in the United States has been dramatic. Between 2012 and 2023, overall stimulant dispensing in the U.S. increased by 60%, climbing from 50.4 million prescriptions to 80.8 million. The number of patients receiving a stimulant prescription grew by 48% over that same period, from 11.1 million to 16.5 million people. By 2023, amphetamine/dextroamphetamine formulations (the Adderall family) accounted for 49% of all stimulant prescriptions, making it the single most commonly prescribed stimulant in the country.
The growth hasn’t been evenly distributed. Prescriptions increased most sharply among adults aged 31 to 40 (up 240%) and 41 to 50 (up 164%), reflecting a broader trend of adults seeking ADHD diagnoses later in life. Prescribing also grew faster among women (up 92%) than men (up 36%), and by 2022, more stimulant prescriptions were written for female patients than male patients overall.
The Ongoing Shortage
Despite decades on the market and multiple generic manufacturers, Adderall has faced persistent supply problems in recent years. Multiple manufacturers have reported shortages tied to a combination of increased demand and delays in sourcing the active ingredient. Several companies, including Mylan, Zydus, and Solco, have discontinued their immediate-release tablets entirely. Others like Teva, Sandoz, and Lannett have specific strengths on back order or in limited supply. Rhodes has all of its immediate-release strengths on back order with no estimated release date.
The shortage is partly a supply chain issue and partly a regulatory one. Because amphetamine is a Schedule II controlled substance, the DEA sets annual production quotas that limit how much manufacturers can produce. When demand surges faster than quotas adjust, shortages follow. For patients, this has meant pharmacy-hopping, switching between manufacturers, or temporarily going without medication.